Business Wire

Over Half of Consumers Will Pay More for Brands That Are Transparent About AI Data Use, New Usercentrics Research Finds

24.6.2026 08:30:00 CEST | Business Wire | Press release

Share

52% of consumers globally will pay a 7% premium for AI transparency — rising to 73% in Germany. Almost half have already taken an action with a direct revenue consequence.

AI transparency has become a commercial differentiator, and it's reshaping where brand revenue is won — or lost.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623804294/en/

Over half (52%) of consumers globally will pay more for brands that are transparent about how they use AI with their data at an average 7% premium. In Germany, that figure rises to 73% of consumers willing to pay a 9% premium, the highest of any market.

The finding comes from the second annual State of Digital Trust 2026 Report, commissioned by Usercentrics, a leading data privacy technology company, and conducted by Sapio Research across 11,000 consumers in seven markets.

The opportunity for brands that act is matched by the cost of inaction. Almost half (47%) of consumers surveyed have taken at least one action with a direct revenue consequence in the past six months because of concerns about how their data was being used in AI — canceling a subscription, switching to a competitor, or reducing their spend. For a brand with one million customers, that translates to up to 240,000 purchase-affecting decisions in six months driven entirely by AI data concerns.

The actions consumers are taking are concrete:

  • 35% have taken two or more of these actions — canceled, switched to a competitor, or reduced spend
  • 24% avoided trying a new product from that brand
  • 20% switched to a competitor they believed handled AI data more responsibly
  • 20% reduced their spending
  • 31% warned friends and family or complained publicly

"Consumers are making purchasing decisions based on how brands handle their data, and over half are willing to pay more to the ones that get it right. The brands that move first won't just earn the premium. They'll earn a category position that's almost impossible to compete against once it's established," said Tilman Harmeling, Strategy & Market Intelligence, Usercentrics.

Why 2026 is different

Three forces have collided in the past 12 months to accelerate consumer decision-making on AI data.

AI has moved from answering questions to taking actions. Agentic AI now accesses financial accounts, calendars, and customer records on behalf of users, raising the stakes of data misuse in ways consumers directly feel.

Privacy regulation is expanding faster than at any point since GDPR, with the EU AI Act in active enforcement, over twenty US states operating distinct privacy laws, and UK regulators publishing an agentic AI governance paper in March 2026.

Consumers have crossed from passive acceptance into active decision-making. A steady accumulation of data breaches, AI training controversies, and cookie banner enforcement actions has shifted the baseline. Trust in AI with personal data has fallen: 52% of consumers now trust AI less than humans with their data, up from 48% in 2025 – the largest single year-on-year movement in the dataset.

Market-by-market findings

Consumer behavior on AI trust varies significantly across the seven markets covered in the study:

  • Germany: 73% will pay more for AI transparency, at a 9% average premium — the highest globally. 75% have acted against a brand over AI data concerns.
  • Italy: 42% will pay more for AI transparency, at the lowest average premium of any market (5%).
  • Netherlands: 77% find AI-driven personalization intrusive, the highest globally. Only 35% will pay more for AI transparency, the lowest globally.
  • Spain: 76% have acted against a brand over AI data concerns, the highest of any market. 92% have taken some form of data protection action in the past six months.
  • Sweden: 69% trust banking with their data, the highest of any market. Yet 56% don't have a good understanding of how their data is collected, also the highest. Sweden joins the study for the first time in 2026.
  • United Kingdom: 80% would stop using a service if their data was misused, the highest of any market. Data privacy rights awareness improved more in the UK than anywhere else this year (43% unaware, down from 50% in 2025).
  • United States: 50% will pay more for AI transparency. Only 39% trust government services with their data — the lowest of any market.

Additional key findings

  • 71% of consumers are concerned that AI-driven personalization feels intrusive
  • 48% click "accept all" on cookies less often than three years ago, up from 46% in 2025
  • Privacy-aware consumers are nearly three times more comfortable with personalization of their online experience than privacy-unaware consumers (53% versus 19%)

Read the full State of Digital Trust 2026 report here.

About the research

The State of Digital Trust 2026 is the second annual study commissioned by Usercentrics and conducted by Sapio Research. The survey polled 11,000 consumers across seven markets: the UK, USA, Germany, Spain, Italy, the Netherlands, and Sweden. Fieldwork was conducted in March 2026. Sweden joins the study for the first time this year; year-on-year comparisons exclude Swedish data.

About Usercentrics

Usercentrics is a leading data privacy technology company that helps businesses collect, manage, and activate consented data with confidence. Trusted by 2.4 million websites and apps across 195 countries, the company processes more than 8.8 billion user consents every month. Through its platform — spanning consent management, server-side tagging, and AI data governance — Usercentrics gives businesses the compliance infrastructure to grow, innovate, and operate responsibly in an AI-first world. Learn more at usercentrics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260623804294/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye